This is a working overview of heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-17 and is reviewed periodically as new material appears.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
The blood clot is only a temporary solution to stop bleeding; tissue repair is needed. Small interruptions in the endothelium are handled by physiological mechanisms; large interruptions by a trauma surgeon. The fibrin is slowly dissolved by the fibrinolytic enzyme, plasmin, and the platelets are cleared by phagocytosis. Platelets release platelet-derived growth factor (PDGF), a potent chemotactic agent; and TGF beta, which stimulates the deposition of extracellular matrix; fibroblast growth factor, insulin-like growth factor 1, platelet-derived epidermal growth factor, and vascular endothelial growth factor. Local application of these factors in increased concentrations through platelet-rich plasma (PRP) is used as an adjunct in wound healing.
Guanosine monophosphate synthetase, (EC 6.3.5.2) also known as GMPS is an enzyme that converts xanthosine monophosphate to guanosine monophosphate. In the de novo synthesis of purine nucleotides, IMP is the branch point metabolite at which point the pathway diverges to the synthesis of either guanine or adenine nucleotides. In the guanine nucleotide pathway, there are 2 enzymes involved in converting IMP to GMP, namely IMP dehydrogenase (IMPD1), which catalyzes the oxidation of IMP to XMP, and GMP synthetase, which catalyzes the amination of XMP to GMP.
His publications also highlight the importance of patient happiness, as well as the well-being of the treating physician. Strengthening family support, advancing social acceptance, and addressing patient emotions are other elements he considers essential to delivering person-centred care.69 He has also highlighted the value of indigenous methods for lifestyle modification and personal hygiene in improving person-centred care.123,166 Kalra has proposed several frameworks to help clinicians integrate the above principles into routine practice.129,161,162 These frameworks have been widely cited. In collaboration with researchers in Morocco, he published the SURE framework outlining the “glycaemic personality” of patients, enabling more tailored therapeutic choices. In another publication, he described the Motivation–Opportunity–Capability (MOC) model for obesity care, underscoring the importance of understanding patient behaviour and aligning therapeutic approaches with their opportunities and capabilities. Kalra’s contribution to original research includes participation in multicentric international collaborative studies that have advanced understanding of person-centred management. In the three-year, pan-India longitudinal study on diabetes outcomes (the LANDMARC trial), data are being collected on trends in diabetic complications, physician treatment strategies, and correlations between treatment, control, and complications in the Indian setting.
Sample preparation for mass spectrometry is used for the optimization of a sample for analysis in a mass spectrometer (MS). Each ionization method has certain factors that must be considered for that method to be successful, such as volume, concentration, sample phase, and composition of the analyte solution. Quite possibly the most important consideration in sample preparation is knowing what phase the sample must be in for analysis to be successful. In some cases the analyte itself must be purified before entering the ion source. In other situations, the matrix, or everything in the solution surrounding the analyte, is the most important factor to consider and adjust. Often, sample preparation itself for mass spectrometry can be avoided by coupling mass spectrometry to a chromatography method, or some other form of separation before entering the mass spectrometer. In some cases, the analyte itself must be adjusted so that analysis is possible, such as in protein mass spectrometry, where usually the protein of interest is cleaved into peptides before analysis, either by in-gel digestion or by proteolysis in solution.
Since about 2005, body scanners have been used primarily at airports for security (passenger) screening. Passive scanners detect the natural radiation emitted by a person's body and use it to locate objects worn or concealed on the body. Active systems also use artificial radiation to improve detection by analyzing the backscatter. A distinction is made between body scanners that use ionizing radiation (usually X-rays) and those that use non-ionizing radiation (terahertz radiation).
Sources: en.wikipedia.org
=== Kinetic isotope effects === Kinetic isotope effect (KIE) occurs in irreversible reactions, such as methanogenesis, and can deviate methane clumped isotopologue composition from its thermodynamic equilibrium. Normally, KIE significantly drives
differs when considering the effects of vaccinations and when the real-time dependence of fatality and recovery rates diverge. These differences have been highlighted for stationary ratios and gradually decreasing fatality rates. The case of stationary ratios allows one to construct a diagnostics method to extract analytically all SIRVD model parameters from measured COVID-19 data of a completed pandemic wave.
The National Emergency Management Agency issues a tsunami advisory for all coastal areas in New Zealand following a 8.8 magnitude earthquake off the eastern coast of Kamchatka Peninsula. Gloriavale's Overseeing Shepherd Howard Temple pleads guilty to 12 charges including indecent assault, indecency and common assault. 31 July: Stuff shuts down 15 community newspapers including the Western Leader and The Hutt News. Dunedin-based media company Allied Press rebrands as Allied Media. The New Zealand Parliament passes legislation repealing a 2018 law limiting new oil and gas exploration permits off the coast of Taranaki. Director of the Federal Bureau of Investigation Kash Patel opens a new FBI attaché office in Wellington to boost bilateral law enforcement cooperation between the United States and New Zealand. Te Pāti Māori (Māori Party) files urgent High Court proceedings calling on the Electoral Commission, Ministry of Justice and the Ombudsman to investigate allegations that Māori voters had been removed from the Māori electoral roll without their consent. The Government introduces a law limiting voter enrolment before elections, banning prisoner voting, and starting voting 12 days early, amid rights concerns and opposition criticism.
=== Flow cell === The eluant from the column passes through one or more flow cells to measure the concentration of protein in the eluant (by UV light absorption at 280 nm). The conductivity cell measures the buffer conductivity, usually in millisiemens/cm, which indicates the concentration of salt in the buffer. A flow cell which measures pH of the buffer is also commonly included. Usually each flow cell is connected to a separate electronics module which provides power and amplifies the signal.
== Relevant Pharmacokinetics == The structure of procaricain shows a pro-region connected to an active enzyme. Caricain is regarded as a cysteine endopeptidase, that is, it functions through the action of a cysteine residue at its active site and it is capable of hydrolysing peptide bonds that are well within the N-terminus and C-terminus of the substrate. With proenzymes, the pharmacokinetics would be governed normally by the rate of intramolecular cleavage to produce the active form of the enzyme. The catalytic site is located in a cleft between two lobes and binding of the substrate needs to occur before activity is available. However, as the active form is the one which is present in the processed latex, the rate limiting step in the reaction with proteins will be simply the conversion of the enzyme-substrate complex to product with the regeneration of the enzyme. The hydrolysis of a peptide bond is however, an automatically favourable reaction. Proteolytic enzymes, such as caricain, catalyse the hydrolysis of a peptide bond at rates which depend upon certain chemical groups from amino acids in the neighbourhood of this bond. Hydrolysis is generally confined to peptides made from amino acids of the L-configuration. The rate varies linearly with low substrate concentration (first-order kinetics) and becomes independent at high concentrations of substrate (zero order kinetics). The kinetics depends upon the rapid formation of an enzyme substrate complex which is then slowly converted to the product in the rate determining step which regenerates the enzyme.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.